Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.

ABSTRACT:

Objective

Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states. We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (SI) and glucose tolerance status.

Research design and methods

A total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years.

Results

Pioglitazone reduced IGT conversion to diabetes by 72% in association with improved β-cell function by 64% (insulin secretion/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin co

SUBMITTER: Tripathy D 

PROVIDER: S-EPMC4179517 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature